The Prognostic Role of Maximum Standardized Uptake Value of 18 F-FlouroDeoxy Glucose Positron Emission Tomography-Computed Tomography in Head and Neck Cancer Patients Undergoing Chemoradiotherapy.

AIMS AND OBJECTIVES: This retrospective study aims at correlating the pre- and post-therapy maximal standardized uptake values (SUVmax) of the whole-body 18-flourodeoxy glucose positron emission tomography (FDG-PET) scan with tumor response in patients with head and neck squamous cell cancer undergoing chemoradiotherapy. MATERIALS AND METHODS: Data for this retrospective study were taken from the clinical records of 20 evaluable head and neck cancer patients who had availed treatment and evaluation at our institute during the previous year (March 2017-April 2018). All these above-mentioned patients had undergone chemoradiation at our center for locally advanced squamous cell carcinoma of the head and neck and had undergone pre- and post-therapy whole-body FDG PET scan. The posttherapy PET-computed tomography (CT) was advised after 8 weeks' postcompletion of therapy. During the PET CT scan, images were acquired 1 h after injection of FDG. Pre- and post-therapy SUVmax were recorded and correlated with immediate treatment response. RESULTS: The mean pretherapy SUVMax of the primary tumor was 10.27 ranging from 4.5 to 26.17. The mean pretherapy SUVMax of the node was 5.34 ranging from 0 to 17.9. The mean time of recording the posttherapy SUVMax was 3 months (range 2-5 months). The mean posttherapy SUVMax of the primary tumor was 1.05 ranging from complete metabolic response to 6.4. The mean posttherapy SUVMax of the node was 0.7 ranging from complete metabolic response to 5.43. The statistical analysis based on Wilcoxon-Signed Rank test revealed a statistically significant difference in the pre- and post-therapy SUVmax values for both primary tumor (P < 0.001) and regional node (P = 0.001). Majority of patients (n = 15) showed clinical remission; however, five patients had progressive disease at the time of evaluation. CONCLUSION: Although the retrospective study revealed that complete responders had a statistically significant reduction in the posttherapy SUVmax in comparison to the pretherapy SUVmax it failed to identify a cutoff value for pretherapy SUVmax which could predict the probable outcome of therapy. In view of the same further prospective studies need to be conducted with larger patient numbers including various other tumor metabolic markers for greater clarity.

18F-FDG PET/CT scanning: Biological effects on patients: Entrance surface dose, DNA damage, and chromosome aberrations in lymphocytes.

Positron Emission Tomography/Computed Tomography (PET/CT), a combination of PET and CT, is used in tumor staging, therapy planning, and treatment response monitoring. During PET imaging, patients receive low doses of radiation, which can induce an adaptive response and necessitate higher doses for therapeutic efficacy. Higher doses may augment toxicity to normal cells. We are examining the effects of short-term, low-dose exposures to ionizing radiation. Entrance Surface Dose (ESD) to head, shoulders, and pelvis regions were measured using Li2B4O7: Mn thermoluminescent dosimeters. Induced DNA damage in lymphocytes was measured using γ-H2AX, p53Ser-15, chromosome aberrations, and micronucleus formation in subjects (n = 25) who underwent 18F-FDG PET/CT. The mean ESD ± SD value obtained were 32.40 ± 16.86, 32.58 ± 14.22, 32.02 ± 15.42, 43.55 ± 18.25 and 42.80 ± 24.67 mGy for the head, right shoulder, left shoulder, right pelvic, and left pelvic regions, respectively. The effective doses of PET and CT ranged from 4.01 to 6.61 and 16.40-72.18 mSv, respectively, and the obtained Dose Length Product (DLP) varied from 1093 to 4812 mGy*cm. There was no correlation between DLP and ESD (r2 = 0.1). The chromosome aberration assay showed a significant increase (p < 0.05), post-scanning vs. pre-scanning; the γ-H2AX, p53Ser-15, and micronucleus assays did not show significant increases. Induced DNA damage showed inter-individual variation among the study subjects. Our results imply that the patients received a biologically significant dose during 18F-PET/CT scanning and precautions may be needed to reduce any long-term risk of exposure.

Hydronephrosis severity score: an objective assessment of hydronephrosis severity in children-a preliminary report.

The main challenge in the management of antenatally diagnosed hydronephrosis and ureteropelvic junction obstruction (UPJO) is to differentiate the one that is likely to resolve from the pathological one. In this study, a new hydronephrosis severity score (HSS), combining ultrasonographic and renographic parameters, has been developed. Hydronephrosis severity score was analyzed with regard to its usefulness in assessing the severity of UPJO, postoperative resolution, and interobserver reliability. METHODS: Hydronephrosis severity score was devised with three parameters: differential renal function (DRF), drainage curve pattern, and ultrasonogram grade (Table 1). Hydronephrosis severity score ranges were divided as 0-4, mild; 5-8, moderate; and 9-12, severe and compared with clinical outcomes (resolution, persistence, or surgical intervention) by retrospective case record review of children with unilateral UPJO. Among those who underwent surgery, surgical outcomes were compared with changes in HSS at 6-month follow-up. Hydronephrosis severity score was computed by three observers, and interobserver variability was calculated. RESULTS: A total of 125 case records (male:female = 93:32; right:left = 44:81) were analyzed. Among the patients analyzed, none (0/59) with HSS 0-4 warranted surgery, whereas 1 of 35 patients with HSS 5-8 underwent surgery, and all (31/31) with HSS 9-12 underwent surgery (P = 0.001). Overall, hydronephrosis resolved in 65, persisted in 28, and required surgery in 32 patients. Mean (standard deviation) HSS was 2.1 (0.75) in whom it resolved, 6.2 (0.78) in whom it persisted, and 10.2 (0.79) in those who underwent surgery (analysis of variance P = 0.001). Among those who underwent surgery, a better recovery of HSS was noted in younger infants (aged 2-5 months) with higher pre-operative DRF. There was 94.4% median agreement between radiologists and the surgeon (kappa 0.851), indicating a very good interobserver agreement. DISCUSSION: Loss of DRF on progressive renograms remains the accepted criterion of significant UPJO although the lost function does not always recover after pyeloplasty. Newer scoring systems keep evolving to predict the need for surgery as well as assess resolution of UPJO, and the study's preliminary report suggests that HSS could turn out to be one such useful tool. In this study, those who deteriorated were the ones with HSS ≥9. One can use this as a criterion and decide on intervention before DRF deterioration. Hydronephrosis severity score could also be applied as an objective parameter for quantifying improvement/deterioration after surgery and comparing outcomes across centers. The drawbacks of the present study are its small size and the retrospective nature. Further prospective studies are required to validate the usefulness of HSS.